News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|November 4, 2024

Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

Author(s)Nicholas J. Silvestri, MD, FAAN, Ali Habib, MD, Neelam Goyal, MD

Key Takeaways

FcRn-targeting agents for gMG vary in their mechanisms, primarily by inhibiting FcRn to lower pathogenic IgG levels or modulating immune responses.
Both approved and investigational FcRn-targeting drugs possess distinct pharmacological profiles, impacting their therapeutic applications.
The development of these therapies marks a significant advancement in gMG management, enhancing treatment options and patient outcomes.

SHOW MORE

Panelists discuss how various approved and investigational FcRn-targeting agents differ in their mechanisms of action for treating generalized myasthenia gravis (gMG).

Episodes in this series

EP. 1 Generalized Myasthenia Gravis Presentation and Diagnosis

EP. 1 Generalized Myasthenia Gravis Presentation and Diagnosis

EP. 2 Generalized Myasthenia Gravis Classification and Treatment Strategy

EP. 2 Generalized Myasthenia Gravis Classification and Treatment Strategy

EP. 3 Pathophysiology and Standard of Care in Generalized Myasthenia Gravis

EP. 3 Pathophysiology and Standard of Care in Generalized Myasthenia Gravis

EP. 4 Outcome Measures in Generalized Myasthenia Gravis

EP. 4 Outcome Measures in Generalized Myasthenia Gravis

EP. 5 Complement Inhibitors for Treatment of Generalized Myasthenia Gravis

EP. 5 Complement Inhibitors for Treatment of Generalized Myasthenia Gravis

EP. 6 Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

EP. 6 Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

EP. 7 Factors Guiding Treatment Selection in Generalized Myasthenia Gravis

EP. 7 Factors Guiding Treatment Selection in Generalized Myasthenia Gravis

EP. 8 Combination Therapy in Generalized Myasthenia Gravis and Treatment of Newly Diagnosed Patients

EP. 8 Combination Therapy in Generalized Myasthenia Gravis and Treatment of Newly Diagnosed Patients

EP. 9 Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis

EP. 9 Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis

EP. 10 Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis

EP. 10 Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis

EP. 11 Use of Targeted Agents in Generalized Myasthenia Gravis

EP. 11 Use of Targeted Agents in Generalized Myasthenia Gravis

EP. 12 Management of Generalized Myasthenia Gravis in Pediatric Patients

EP. 12 Management of Generalized Myasthenia Gravis in Pediatric Patients

EP. 13 Unmet Needs in Generalized Myasthenia Gravis

EP. 13 Unmet Needs in Generalized Myasthenia Gravis

EP. 14 Generalized Myasthenia Gravis Pipeline

EP. 14 Generalized Myasthenia Gravis Pipeline

EP. 15 New Data from AANEM 2024 in Generalized Myasthenia Gravis

EP. 15 New Data from AANEM 2024 in Generalized Myasthenia Gravis

EP. 16 Clinical Pearls for Management of Generalized Myasthenia Gravis

EP. 16 Clinical Pearls for Management of Generalized Myasthenia Gravis

Video content above is prompted by the following:

A number of agents targeting the neonatal Fc receptor (FcRn) have recently been approved or are under investigation to treat gMG. What are the differences regarding mechanism of action among the following approved or investigational FcRn-targeting agents?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Paul G. Auwaerter, MD, MBA; Paul P. Doghramji, MD, FAAFP; Aruna Subramanian, MD

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

In-Person + Virtual Event

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

November 21, 2025

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

John F. Brandsema, MD; Abigail N. Schwaede, MD; Samuel J. Mackenzie, MD, PhD

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

James F. Howard Jr, MD

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

John Brandsema, MD; Neelam Goyal, MD

Identifying and Treating CIDP in the Modern Era

Identifying and Treating CIDP in the Modern Era

Jeffrey A. Allen, MD; Karissa L. Gable, MD

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

John Brandsema, MD; Carla D. Zingariello, DO

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency

New Phase 3 Study to Evaluate Remibrutinib in Generalized Myasthenia Gravis Treatment

New Study to Assess Complement Inhibitor Iptacopan in Generalized Myasthenia Gravis

Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS

Evolving Landscape of Myasthenia Gravis Treatment and Unmet Needs: Leila Darki, MD

© 2025 MJH Life Sciences^®

All rights reserved.